Vistagen Therapeutics (VTGN) Profit After Tax (2011 - 2026)

Vistagen Therapeutics has reported Profit After Tax for 16 years, with the latest figure at -$16.3 million in Q1 2026.

• Quarterly Profit After Tax fell 19.3% year-over-year to -$16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.7 million (down 35.51% YoY) and the FY2026 annual result came in at -$69.7 million, down 35.54% from the prior year.
• Profit After Tax climbed to -$16.3 million in Q1 2026 per VTGN's latest filing, from -$18.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$6.4 million in Q4 2023 and troughed at -$19.8 million in Q2 2022.
• A 5-year average of -$13.3 million and a median of -$13.6 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax sank 168.68% in 2022, then surged 65.09% in 2023.
• Over 5 years, Profit After Tax stood at -$9.8 million in 2022, then jumped by 34.95% to -$6.4 million in 2023, then sank by 121.87% to -$14.1 million in 2024, then slumped by 34.14% to -$18.9 million in 2025, then grew by 13.89% to -$16.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$16.3 million, -$18.9 million, and -$19.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.